Supplementary Online Content

Olivier CB, Mulder H, Hiatt WR, et al. Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. *JAMA Cardiol.* Published online December 12, 2018. doi:10.1001/jamacardio.2018.4171

eMethods. Definition of myocardial infarction (MI)

eTable 1. Adjustment variables for risk of cardiovascular death and acute limb ischemia following myocardial infarction

eTable 2. Baseline characteristics of patients included by region

eTable 3. Incidence rates of myocardial infarction by region

eTable 4. Electrocardiography characteristics of the first myocardial infarction during follow-up

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2018 American Medical Association. All rights reserved.

eMethods. Definition of myocardial infarction (MI)

For a spontaneous MI, detection of rise and/or fall of cardiac biomarkers, preferably troponin, with at least one value above the 99th percentile if available or the upper reference limit (URL) from the local lab, together with evidence of myocardial ischemia with at least one of the following:

- o Clinical presentation consistent with ischemia
- ECG evidence of acute myocardial ischemia
- New pathological Q-waves
- Autopsy evidence of acute MI
- Sudden unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by presumably new ST-elevation or new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood.
- Percutaneous Coronary Intervention-Related Myocardial Infarction: Peri-PCI MI is defined by any of the following criteria. Symptoms of cardiac ischemia are not required.
 - 1. Biomarker elevations within 48 hours of PCI:
 - Troponin or CK-MB (preferred) >3 x URL and
 - No evidence that cardiac biomarkers were elevated prior to the procedure; OR
 - Both of the following must be true:
 - \geq 50% increase in the cardiac biomarker result
 - Evidence that cardiac biomarker values were decreasing (e.g., two samples 3 to 6 hours apart) prior to the suspected MI
 - 2. New pathological Q-waves
 - 3. Autopsy evidence of acute MI
- Coronary Artery Bypass Grafting-Related Myocardial Infarction: Peri- CABG MI is defined by the following criteria. Symptoms of cardiac ischemia are not required.
 - 1. Biomarker elevations within 72 hours of CABG:
 - Troponin or CK-MB (preferred) >5 x URL and
 - No evidence that cardiac biomarkers were elevated prior to the procedure; **OR**
 - Both of the following must be true:
 - \geq 50% increase in the cardiac biomarker result
 - Evidence that cardiac biomarker values were decreasing (e.g., two samples 3 to 6 hours apart) prior to the suspected MI.
 - AND
 - 2. One of the following:
 - New pathological Q-waves persistent through 30 days
 - New persistent non-rate-related LBBB
 - Angiographically documented new graft or native coronary artery occlusion
 - Other complication in the operating room resulting in loss of myocardium
 - Imaging evidence of new loss of viable myocardium
 - OR (regardless of items 1 and 2 above)
 - 3. Autopsy evidence of acute MI

eTable 1. Adjustment variables for risk of cardiovascular death and acute limb ischemia

following myocardial infarction

MI type	CV death	ALI
Any	region, age, diabetes, prior PCI, prior MI, inclusion criteria, prior carotid revascularization or stenosis, baseline Rutherford score, prior minor amputation, beta blocker use, prior CHF, prior TIA, prior CABG, tobacco use, sex, prior statin use, prior stroke and prior major amputation	region, age, diabetes, prior PCI, prior MI, inclusion criteria, prior carotid revascularization or stenosis, baseline Rutherford score, prior minor amputation, beta blocker use, prior CHF, prior TIA, prior CABG, tobacco use, sex, prior statin use, and baseline ABI
Туре 1	diabetes, prior MI, region, prior PCI, prior carotid revascularization/stenosis, baseline Rutherford score, inclusion criteria, prior CHF, prior TIA, prior stroke, prior statin use, and prior major amputation	diabetes, prior MI, region, prior PCI, prior carotid revascularization/stenosis, baseline Rutherford score, inclusion criteria, prior CHF, prior TIA, prior statin use and baseline ABI
Type 2	age, sex, weight, diabetes, region, prior PCI, prior carotid revascularization/stenosis, baseline Rutherford score, inclusion criteria, prior CHF, beta blocker use, prior TIA, prior statin use, prior stroke, and prior major amputation	age, sex, weight, diabetes, region, prior PCI, prior carotid revascularization/stenosis, baseline Rutherford score, inclusion criteria, prior CHF, beta blocker use, prior TIA, prior statin use, and baseline ABI

ABI, ankle-brachial index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

eTable 2. Baseline characteristics of patients included by region

America (h=1740) Asia (N=1602) Europe (N=7498) America (N=3045) Age, years, median (25th, 75th) 67, 61-74 70, 63-75 65, 59-71 67, 61-73 Female sex 664 (38.2%) 330 (20.6%) 1828 (24.4%) 1066 (35.0%) Weight, Kg, median (25th, 75th) 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Inclusion Criteria for 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Randomization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI or TBL criteria 1149 (66.0%) 440 (27.5%) 3626 (48.4%) 795 (26.1%) ABI or TBL emean (SD) 0.67, (0.22) 0.44, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford classification 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Miaor tissue loss 14 (0.5%) 17 (1.1%) 26 (0.3%) 140 (1%) Major tissue loss 11 (0.8%) 42 (2.6%) 188 (2.5%) 97 (3.2%) <		South/Central			North	
Characteristic (N=1402) (N=7498) (N=7498) (N=3045) Age, years, median (25th, 75th) 67, 61-74 70, 63-75 65, 59-71 67, 61-73 Female sex 664 (38.2%) 330 (20.6%) 1828 (24.4%) 1066 (35.0%) Weight, kg, median (25th, 75th) 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Inclusion Criteria for Previous revascularization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.11) ABI value, mean (SD) 0.66, (0.20) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford classification 730 (45.6%) 4033 (44.0%) 169 (20.0%) Asymptomatic 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 99 (1.3%) Minor insue loss 44 (2.5%) 48 (2.6%) 99 (1.3%) 16 (0.5%) Major amputation 175 (10.1%) 82 (5.1%) 272 (3.6%)<		America	Asia	Europe	America	
Age, years, median (25th, 75th) 67, 61-74 70, 63-75 65, 59-71 67, 61-73 Female sex 664 (38.2%) 330 (20.6%) 1828 (24.4%) 1066 (35.0%) Weight, kg, median (25th, 75th) 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Inclusion Criteria for Randomization 9 70-94 82, 70-94 Previous revascularization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI or TBI criteria 1149 (66.0%) 440 (27.5%) 3626 (44.4%) 795 (26.1%) ABI or TBI criteria 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) Limb symptoms by Rutheford 1181 value, mean (SD) 0.57, (0.22) 0.44, (0.16) 1111 (17.5%) 609 (20.0%) Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 609 (22.7%) Major tissue loss 14 (0.6%) 17 (1.1%) 26 (0.3%) 49 (0.5%) Major amputation above the ankle 108 (6.3%) <	Characteristic	(N=1740)	(N=1602)	(N=7498)	(N=3045)	
Female sex 664 (38.2%) 330 (20.6%) 1828 (24.4%) 1066 (35.0%) Weight, kg. median (25th, 75th) 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Inclusion Criteria for Randomization 79, 70-89 82, 70-94 Previous revascularization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.14) 0.64, (0.12) TB value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.52, (0.14) 0.64, (0.12) TB value, mean (SD) 0.57, (0.22) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford classification 998 (57.4%) 730 (45.6%) 4053 (54.1%) 162 (55.%) Severe claudication 598 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 4053 (54.1%) 162 (55.%) Mior tissue loss 11 (0.6%) 177 (1.1%) 26 (0.3%) 4 (0.1%) Mior tissue loss 11 (0.6%) 1002 (62.5%)	Age, years, median (25th, 75th)	67, 61-74	70, 63-75	65, 59-71	67, 61-73	
Weight, kg, median (25th, 75th) 74, 65-84 62, 54-70 79, 70-89 82, 70-94 Inclusion Criteria for Randomization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.21) ABI value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) ABI value, mean (SD) 0.57, (0.22) 0.44, (0.16) 0.44, (0.16) Limb symptoms by Rutherford 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (22.0%) Severe claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Major tissue loss 11 (0.6%) 17 (1.1%) 26 (0.3%) 4 (0.5%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 1	Female sex	664 (38.2%)	330 (20.6%)	1828 (24.4%)	1066 (35.0%)	
Inclusion Criteria for Randomization S91 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.21) ABI oralue, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) TBI value, mean (SD) 0.57, (0.22) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford classification 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (20.0%) Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 44 (2.6%) 188 (2.5%) 97 (3.2%) Minor tissue loss 11 (0.6%) 17 (1.1%) 26 (0.3%) 4 (0.1%) Major amputation above the ankle 108 (6.3%) 445 (2.5%) 430 (3.0%) 76 (2.5%) Medical History T 1 1131 (65.0%) 1002 (62.5%) 452 (60.3%) 1146 (37.6%) 2 <	Weight, kg, median (25th, 75th)	74, 65-84	62, 54-70	79, 70-89	82, 70-94	
Randomization Strip Construction Strip Strip	Inclusion Criteria for					
Previous revascularization 591 (34.0%) 1162 (72.5%) 3872 (51.6%) 2250 (73.9%) ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.21) ABI value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) TBI value, mean (SD) 0.57, (0.22) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford	Randomization					
ABI value, mean (SD) 0.70, (0.23) 0.81, (0.25) 0.76, (0.23) 0.82, (0.21) ABI or TBI criteria 1149 (66.0%) 440 (27.5%) 3626 (48.4%) 795 (26.1%) ABI value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) Limb symptoms by Rutherford classification 988 (57.4%) 730 (45.6%) 4003 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 1488 (2.5%) 97 (3.2%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major tissue loss 11 (0.6%) 17 (1.1%) 26 (0.3%) 4 (0.1%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation 175 (10.1%) 82 (5.1%) 272 (3.6%) 76 (2.5%) Number of vascular beds affected 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 1308 (14.5%) 608 (20.0%) Prior CAD </td <td>Previous revascularization</td> <td>591 (34.0%)</td> <td>1162 (72.5%)</td> <td>3872 (51.6%)</td> <td>2250 (73.9%)</td>	Previous revascularization	591 (34.0%)	1162 (72.5%)	3872 (51.6%)	2250 (73.9%)	
ABI or TBI criteria 1149 (66.0%) 440 (27.5%) 3626 (48.4%) 795 (26.1%) ABI value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) TBI value, mean (SD) 0.57, (0.22) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Linb symptoms by Rutherford 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (20.0%) Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Major tissue loss 41 (2.5%) 42 (2.6%) 188 (2.5%) 49 (1.6%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Mumber of vascular beds affected Number of vascular beds affected Number of vascular beds affected 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) Prior TIA 42 (2.4%) 62 (3.9%) 121 (2.8%) 129 (42.4%) 62 (3.9%) <t< td=""><td>ABI value, mean (SD)</td><td>0.70, (0.23)</td><td>0.81, (0.25)</td><td>0.76, (0.23)</td><td>0.82, (0.21)</td></t<>	ABI value, mean (SD)	0.70, (0.23)	0.81, (0.25)	0.76, (0.23)	0.82, (0.21)	
ABI value, mean (SD) 0.66, (0.20) 0.62, (0.15) 0.62, (0.14) 0.64, (0.12) TBI value, mean (SD) 0.57, (0.22) 0.46, (0.12) 0.49, (0.22) 0.44, (0.16) Limb symptoms by Rutherford	ABI or TBI criteria	1149 (66.0%)	440 (27.5%)	3626 (48.4%)	795 (26.1%)	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	ABI value, mean (SD)	0.66, (0.20)	0.62, (0.15)	0.62, (0.14)	0.64, (0.12)	
Limb symptoms by Rutherford Image: Construct of the symptomatic Image: Construct of the symptomatic of the s	TBI value, mean (SD)	0.57, (0.22)	0.46, (0.12)	0.49, (0.22)	0.44, (0.16)	
classification 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (20.0%) Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (24.3%) 690 (22.7%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major tissue loss 11 (0.6%) 17 (1.1%) 26 (0.3%) 4 (0.1%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation 175 (10.1%) 82 (5.1%) 272 (3.6%) 76 (2.5%) Mumber of vascular beds affected 11131 (65.0%) 1002 (62.5%) 4526 (0.3%) 1146 (37.6%) 2 518 (29.8%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior tTA 42 (2.4%) 62 (3.9%) 1212 (2.8%) 191 (6.3%) Prior	Limb symptoms by Rutherford					
Asymptomatic 128 (7.4%) 553 (34.5%) 1311 (17.5%) 609 (20.0%) Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 1629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Mumber of vascular beds affected 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 238 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior AD 449 (25.8%) 308 (19.2%) 1383 (24.5%) 1437 (47.2%)	classification					
Mild or moderate claudication 998 (57.4%) 730 (45.6%) 4053 (54.1%) 11629 (53.5%) Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation 175 (10.1%) 82 (5.1%) 227 (3.6%) 76 (2.5%) Medical History 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior rtroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAB	Asymptomatic	128 (7.4%)	553 (34.5%)	1311 (17.5%)	609 (20.0%)	
Severe claudication 508 (29.2%) 212 (13.2%) 1818 (24.3%) 690 (22.7%) Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Medical History Image: the start of the star	Mild or moderate claudication	998 (57.4%)	730 (45.6%)	4053 (54.1%)	1629 (53.5%)	
Pain while at rest 51 (2.9%) 42 (2.6%) 188 (2.5%) 97 (3.2%) Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation above the ankle 108 (6.3%) 45 (2.6%) 137 (1.8%) 49 (1.6%) Mumber of vascular beds affected 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (11.2%) 76 (2.5%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2.6%) 129 (25.2%) <t< td=""><td>Severe claudication</td><td>508 (29.2%)</td><td>212 (13.2%)</td><td>1818 (24.3%)</td><td>690 (22.7%)</td></t<>	Severe claudication	508 (29.2%)	212 (13.2%)	1818 (24.3%)	690 (22.7%)	
Minor tissue loss 44 (2.5%) 48 (3.0%) 99 (1.3%) 16 (0.5%) Major tissue loss 11 (0.6%) 17 (1.1%) 26 (0.3%) 4 (0.1%) Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation 175 (10.1%) 82 (5.1%) 272 (3.6%) 76 (2.5%) Medical History	Pain while at rest	51 (2.9%)	42 (2.6%)	188 (2.5%)	97 (3.2%)	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Minor tissue loss	44 (2.5%)	48 (3.0%)	99 (1.3%)	16 (0.5%)	
Major amputation above the ankle 108 (6.3%) 45 (2.8%) 137 (1.8%) 49 (1.6%) Minor amputation 175 (10.1%) 82 (5.1%) 272 (3.6%) 76 (2.5%) Medical History Number of vascular beds affected 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior CABG 141 (8.1%) 76 (4.7%)<	Major tissue loss	11 (0.6%)	17 (1.1%)	26 (0.3%)	4 (0.1%)	
Minor amputation 175 (10.1%) 82 (5.1%) 272 (3.6%) 76 (2.5%) Medical History 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior TIA 42 (2.4%) 62 (3.9%) 1212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Major amputation above the ankle	108 (6.3%)	45 (2.8%)	137 (1.8%)	49 (1.6%)	
Medical History Image: Constraint of the image: Constrent of the image: Constrainton of the image: Constra	Minor amputation	175 (10.1%)	82 (5.1%)	272 (3.6%)	76 (2.5%)	
Number of vascular beds affected 1 1131 (65.0%) 1002 (62.5%) 4525 (60.3%) 1146 (37.6%) 2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior TIA 42 (2.4%) 62 (3.9%) 212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior FI 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) revascularization 122 (7.0%) 148 (191.2%) 614 (8.2%) 705 (23.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class 1	Medical History	,				
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Number of vascular beds affected					
2 518 (29.8%) 493 (30.8%) 2386 (31.8%) 1291 (42.4%) 3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior TIA 42 (2.4%) 62 (3.9%) 212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	1	1131 (65.0%)	1002 (62.5%)	4525 (60.3%)	1146 (37.6%)	
3 91 (5.2%) 107 (6.7%) 587 (7.8%) 608 (20.0%) Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior TIA 42 (2.4%) 62 (3.9%) 212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior MI 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	2	518 (29.8%)	493 (30.8%)	2386 (31.8%)	1291 (42.4%)	
Prior stroke 126 (7.2%) 258 (16.1%) 550 (7.3%) 209 (6.9%) Prior TIA 42 (2.4%) 62 (3.9%) 212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior CAD 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) revascularization 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	3	91 (5.2%)	107 (6.7%)	587 (7.8%)	608 (20.0%)	
Prior TIA 42 (2.4%) 62 (3.9%) 212 (2.8%) 191 (6.3%) Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior MI 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior cABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) revascularization 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior stroke	126 (7.2%)	258 (16.1%)	550 (7.3%)	209 (6.9%)	
Prior CAD 449 (25.8%) 308 (19.2%) 1838 (24.5%) 1437 (47.2%) Prior MI 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior TIA	42 (2.4%)	62 (3.9%)	212 (2.8%)	191 (6.3%)	
Prior MI 319 (18.3%) 158 (9.9%) 1283 (17.1%) 762 (25.0%) Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior CAD	449 (25.8%)	308 (19.2%)	1838 (24.5%)	1437 (47.2%)	
Prior PCI 221 (12.7%) 212 (13.2%) 839 (11.2%) 901 (29.6%) Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior MI	319 (18.3%)	158 (9.9%)	1283 (17.1%)	762 (25.0%)	
Prior CABG 141 (8.1%) 76 (4.7%) 614 (8.2%) 705 (23.2%) Prior carotid stenosis/ revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior PCI	221 (12.7%)	212 (13.2%)	839 (11.2%)	901 (29.6%)	
Prior carotid stenosis/ revascularization 122 (7.0%) 182 (11.4%) 1326 (17.7%) 897 (29.5%) Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior CABG	141 (8.1%)	76 (4.7%)	614 (8.2%)	705 (23.2%)	
revascularization C A C Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	Prior carotid stenosis/	122 (7.0%)	182 (11.4%)	1326 (17.7%)	897 (29.5%)	
Prior atrial fibrillation/flutter 26 (1.5%) 44 (2.7%) 267 (3.6%) 159 (5.2%) Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class	revascularization	((,	
Prior CHF 130 (7.5%) 73 (4.6%) 1385 (18.5%) 340 (11.2%) CCS angina class 1606 (92.3%) 1461 (91.2%) 6194 (82.6%) 2758 (90.6%) I 72 (4.1%) 89 (5.6%) 587 (7.8%) 177 (5.8%) II 49 (2.8%) 39 (2.4%) 567 (7.6%) 86 (2.8%) III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use Never smoker 554 (31.8%) 385 (24.0%) 1693 (22.8%) 352 (11.6%)	Prior atrial fibrillation/flutter	26 (1.5%)	44 (2.7%)	267 (3.6%)	159 (5.2%)	
CCS angina class 1606 (92.3%) 1461 (91.2%) 6194 (82.6%) 2758 (90.6%) I 72 (4.1%) 89 (5.6%) 587 (7.8%) 177 (5.8%) II 49 (2.8%) 39 (2.4%) 567 (7.6%) 86 (2.8%) III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 70 70.8% 385 (24.0%) 1693 (22.8%) 352 (11.6%)	Prior CHF	130 (7.5%)	73 (4.6%)	1385 (18.5%)	340 (11.2%)	
0 1606 (92.3%) 1461 (91.2%) 6194 (82.6%) 2758 (90.6%) I 72 (4.1%) 89 (5.6%) 587 (7.8%) 177 (5.8%) II 49 (2.8%) 39 (2.4%) 567 (7.6%) 86 (2.8%) III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 385 (24.0%) 1693 (22.8%) 352 (11.6%)	CCS angina class					
I 72 (4.1%) 89 (5.6%) 587 (7.8%) 177 (5.8%) II 49 (2.8%) 39 (2.4%) 567 (7.6%) 86 (2.8%) III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 385 (24.0%) 1693 (22.8%) 352 (11.6%)	0	1606 (92.3%)	1461 (91.2%)	6194 (82.6%)	2758 (90.6%)	
II 49 (2.8%) 39 (2.4%) 567 (7.6%) 86 (2.8%) III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 385 (24.0%) 1693 (22.8%) 352 (11.6%)		72 (4.1%)	89 (5.6%)	587 (7.8%)	177 (5.8%)	
III 11 (0.6%) 13 (0.8%) 140 (1.9%) 21 (0.7%) IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 352 (11.6%)	11	49 (2.8%)	39 (2.4%)	567 (7.6%)	86 (2.8%)	
IV 2 (0.1%) 0 (0.0%) 8 (0.1%) 3 (0.1%) Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 355 (24.0%) 1693 (22.8%) 352 (11.6%)		11 (0.6%)	13 (0.8%)	140 (1.9%)	21 (0.7%)	
Chronic Kidney Disease 560 (32.9%) 468 (29.6%) 1381 (19.2%) 896 (30.2%) Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use 385 (24.0%) 1693 (22.8%) 352 (11.6%)	IV	2 (0.1%)	0 (0.0%)	8 (0.1%)	3 (0.1%)	
Family history of CHD 170 (12.9%) 56 (4.6%) 822 (16.4%) 962 (36.9%) Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use	Chronic Kidney Disease	560 (32.9%)	468 (29.6%)	1381 (19.2%)	896 (30.2%)	
Diabetes mellitus type 1 or 2 989 (56.8%) 689 (43.0%) 2447 (32.6%) 1220 (40.1%) Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use	Family history of CHD	170 (12.9%)	56 (4 6%)	822 (16.4%)	962 (36.9%)	
Hypertension 1350 (77.6%) 1123 (70.1%) 5757 (76.8%) 2627 (86.3%) Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use	Diabetes mellitus type 1 or 2	989 (56.8%)	689 (43.0%)	2447 (32.6%)	1220 (40.1%)	
Hyperlipidemia 1232 (70.8%) 883 (55.1%) 5551 (74.1%) 2814 (92.4%) Tobacco Use	Hypertension	1350 (77.6%)	1123 (70.1%)	5757 (76.8%)	2627 (86.3%)	
Tobacco Use Source So	Hyperlipidemia	1232 (70.8%)	883 (55.1%)	5551 (74.1%)	2814 (92.4%)	
Never smoker 554 (31.8%) 385 (24.0%) 1693 (22.8%) 352 (11.6%)	Tobacco Use				(,)	
	Never smoker	554 (31.8%)	385 (24.0%)	1693 (22.8%)	352 (11.6%)	

© 2018 American Medical Association. All rights reserved.

	South/Central		Furone	North America	
Characteristic	(N=1740)	(N=1602)	(N=7498)	(N=3045)	
Former smoker	801 (46.0%)	844 (52.7%)	3221 (43.4%)	1664 (54.6%)	
Current smoker	385 (22.1%)	373 (23.3%)	2502 (33.7%)	1029 (33.8%)	
Medications Before					
Randomization					
Aspirin	1089 (62.6%)	905 (56.5%)	4950 (66.0%)	2327 (76.4%)	
Clopidogrel	217 (12.5%)	551 (34.4%)	2166 (28.9%)	1539 (50.5%)	
Statin	1134 (65.2%)	1012 (63.2%)	5463 (72.9%)	2572 (84.5%)	
ACE inhibitor	706 (40.6%)	205 (12.8%)	3343 (44.6%)	1381 (45.4%)	
Angiotensin receptor blocker	526 (30.2%)	583 (36.4%)	1654 (22.1%)	725 (23.8%)	
Beta-blocker	691 (39.7%)	760 (47.4%)	252 (3.4%)	392 (12.9%)	
Cilostazol	614 (35.3%)	369 (23.0%)	2953 (39.4%)	1704 (56.0%)	

Values are no. (%), unless otherwise indicated. Chronic kidney disease was defined as an estimated glomerular filtration rate of <60 ml/min/1.73m²

ABI, ankle-brachial index; ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHD, coronary heart disease; CHF, congestive heart failure; CI, confidence interval; HR, hazard ratio; MI, myocardial Infarction; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe-brachial index; TIA, transient ischemic attack.

eTable 3. Incidence rates of myocardial infarction by region

Outcome	Asia Rate (# Events)	Central/South America Rate (# Events)	Europe Rate (# Events)	North America Rate (# Events)	
MI	1.87 (71)	0.66 (26)	1.59 (294)	3.96 (292)	
Type 1 MI	1.23 (47)	0.46 (18)	1.01 (188)	2.17 (162)	
Type 2 MI	0.70 (27)	0.15 (6)	0.53 (99)	1.79 (135)	
The median follow-up time was 30 months. Rate calculated as the number of events per 100 patient years of follow-up.					

Characteris	An	Any type		Type 1 MI		Type 2 MI		
STEMI vs. NSTEMI		N	N=683		N=405		N=236	
STEMI		63	(9%)	54	(13%)	1	(<1%)	
NSTEM	11	522	(76%)	312	(77%)	194	(82%)	
Unknow	vn	98	(14%)	39	(10%)	41	(17%)	
New Q-Wave*		N	N=413		N=294		N=91	
Yes		22	(5%)	17	(6%)	3	(3%)	
No		325	(79%)	238	(81%)	71	(78%)	
No ECG available		66	(16%)	39	(13%)	17	(19%)	
Peak Troponin I/T Elevation		N=	N=683		N=405		N=236	
≤1		2	(<1%)	0	(0%)	2	(<1%)	
>1-3		144	(21%)	66	(16%)	76	(32%)	
>3-5	X ULN	51	(7%)	21	(5%)	28	(12%)	
>5-10		79	(12%)	36	(9%)	41	(17%)	
>10		312	(46%)	221	(55%)	70	(30%)	
Missing†		95	(14%)	61	(15%)	19	(8%)	

eTable 4. Electrocardiography characteristics of the first myocardial infarction during follow-up

*Q-wave status was assessed by the site investigator only.

†Ratio not calculated due to missing values for the ULN or peak level elevation of troponin I/T. Values are n (%).

ECG, electrocardiogram; NSTEMI, non-ST-elevation MI; STEMI, ST-elevation MI; ULN, upper limit of normal; others as in Table 1.